Company Profile
Ono Pharmaceutical produces, purchases, and sells pharmaceuticals and diagnostic reagents globally. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors.
Its portfolio also includes Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting, Demser capsules for the symptoms in patients with pheochromocytoma, Mektovi, Velexbru, and Braftovi capsules for malignant tumors, and ADLUMIZ tablets for cancer cachexia Glactiv tablets for type 2 diabetes.
Its portfolio also includes Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease, Onoact intravenous infusion for tachyarrhythmia, Opalmon tablets to treat peripheral circulatory disorder, Coralan for chronic heart failure, Orencia injections for rheumatoid arthritis, Rivastach patches for Alzheimer's disease, Ongentys tablets for Parkinson's disease, Parsabiv for the treatment of secondary hyperparathyroidism, Staybla tablets for overactive bladder, Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis, and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Additionally, it develops products for hepatocellular and urothelial carcinoma. Its portfolio also includes ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer, acute myeloid leukemia, solid tumors, myelodysplastic syndrome, melanoma, T-cell lymphoma, tachyarrhythmia, pemphigus, scleroderma, seizures, diabetic polyneuropathy, neurodegenerative diseases, autoimmune diseases, narcolepsy, and thrombosis.
The company has collaborations with Adimab LLC. Its portfolio also includes Turbine Ltd., Harvard University, Sibylla Biotech, and Congruence Therapeutics. Founded in 1717, Ono Pharmaceutical is headquartered in Osaka, Japan.